Aderhold Neuroleptika minimieren 6.0 - BGSP

37The Icarus Project and Freedom Center: Harm Reduction Guide To Coming Off Psychiatric Drugs (2007)http://theicarusproject.net/HarmReductionGuideComingOffPsychDrugs158 Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y.(2005): Chinese herbal medicine for schizophrenia. CochraneDatabase Syst Rev. 2005 Oct 19;(4):CD003444.Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y, Adams CE.(2007): Chinese herbal medicine for schizophrenia:cochrane systematic review of randomised trials. Br J Psychiatry. 2007 May;190:379-84.Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY.(2002): A double-blind, placebo-controlled trial of extract of Ginkgobiloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 62(11):878-83.Zhang XY, Zhou DF, Su JM, Zhang PY.(2001): The effect of extract of ginkgo biloba added to haloperidol on superoxidedismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol. 21(1):85-8.159 Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M.(1997): Clinical risk following abrupt and gradualwithdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry. 54(1):49-55.Baldessarini R.J., Viguera A.C (1995): Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52(3):189-92.160 Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D.(2007): Guided discontinuation versusmaintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry.68(5):654-61.161 Nishikawa T, Hayashi T, Koga I, Uchida Y.(2007): Neuroleptic withdrawal with remitted schizophrenics: a naturalisticfollow-up study. Psychiatry. 70(1):68-79.162 Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M.(1997): Clinical risk following abrupt and gradualwithdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry. 54(1):49-55.163 Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M.(1997): Clinical risk following abrupt and gradualwithdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry. 54(1):49-55.164 Nishikawa T, Hayashi T, Koga I, Uchida Y.(2007): Neuroleptic withdrawal with remitted schizophrenics: a naturalisticfollow-up study. Psychiatry. 70(1):68-79.Gottdiener, W., & Haslam, N. (2002). Efficacy of individual psychotherapy for schizophrenia: A meta-analysis. EthicalHuman Sciences and Services, 4, 660-687 dt. in Müller T & Matajek N (2007): Empirische Forschung in derPsychosentherapie V&R Göttingen165 Carpenter, W.T. Jr, Buchanan, R.W., Kirkpatrick, B. & Breier, A.F.(1999). Diazepam treatment of early signs ofexacerbation in schizophrenia. American Journal of Psychiatry, 156, 299-303.166 Seikkula, J., Aaltonen, J., Alakare, B., Haarakangas, K. (2006). Five-years experiences of first-episode nonaffectivepsychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy andResearch, 16, 214-228.167 Harrow M, Jobe TH. (2007): Factors involved in outcome and recovery in schizophrenia patients not on antipsychoticmedications: a 15-year multifollow-up study. J Nerv Ment Dis. 195(5):406-14.168 Thornley B, Adams CE, Awad G.(2000): Chlorpromazine versus placebo for schizophrenia. Cochrane Database SystRev. 2000;(2):CD000284.169 Bola, J.R. (2006). Medication-free research in early episode schizophrenia: evidence of long-term harm? SchizophreniaBulletin, 32, 288-96.170 Rappaport M, Hopkins HK, Hall K, et al.(1978): Are there schizophrenics for whom drugs may be unnecessary orcontraindicated? Int Pharmacopsychiatry. 13:100–111.171Wirt RD, Simon W. Differential Treatment and Prognosis in Schizophrenia. Springfield, Ill: Charles C Thomas; 1959.Schooler NR, Goldberg SC, Boothe H, Cole JO.(1967): One year after discharge: community adjustment of schizophrenicpatients. Am J Psychiatry 123(8):986-95.